company background image
BPMC

Blueprint Medicines NasdaqGS:BPMC Stock Report

Last Price

US$47.78

Market Cap

US$2.9b

7D

2.7%

1Y

-38.0%

Updated

30 Jan, 2023

Data

Company Financials +

Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Mkt Cap: US$2.9b

BPMC Stock Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

BPMC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Blueprint Medicines Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Blueprint Medicines
Historical stock prices
Current Share PriceUS$47.78
52 Week HighUS$85.67
52 Week LowUS$40.78
Beta0.63
1 Month Change9.06%
3 Month Change-0.95%
1 Year Change-38.03%
3 Year Change-23.76%
5 Year Change-36.91%
Change since IPO153.21%

Recent News & Updates

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Recent updates

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Feb 17
Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Nov 10
Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Oct 15
Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Most Shareholders Will Probably Find That The CEO Compensation For Blueprint Medicines Corporation (NASDAQ:BPMC) Is Reasonable

May 27
Most Shareholders Will Probably Find That The CEO Compensation For Blueprint Medicines Corporation (NASDAQ:BPMC) Is Reasonable

Blueprint Medicines Corporation (NASDAQ:BPMC) Analysts Are Reducing Their Forecasts For This Year

Feb 18
Blueprint Medicines Corporation (NASDAQ:BPMC) Analysts Are Reducing Their Forecasts For This Year

Blueprint Medicines' (NASDAQ:BPMC) Wonderful 458% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 14
Blueprint Medicines' (NASDAQ:BPMC) Wonderful 458% Share Price Increase Shows How Capitalism Can Build Wealth

Blueprint Medicines Corporation's (NASDAQ:BPMC) Stock Is Going Strong: Have Financials A Role To Play?

Dec 23
Blueprint Medicines Corporation's (NASDAQ:BPMC) Stock Is Going Strong: Have Financials A Role To Play?

Are Blueprint Medicines's (NASDAQ:BPMC) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 27
Are Blueprint Medicines's (NASDAQ:BPMC) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Shareholder Returns

BPMCUS BiotechsUS Market
7D2.7%0.8%2.8%
1Y-38.0%7.1%-9.2%

Return vs Industry: BPMC underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: BPMC underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is BPMC's price volatile compared to industry and market?
BPMC volatility
BPMC Average Weekly Movement6.9%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: BPMC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BPMC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008602Kate Havilandhttps://www.blueprintmedicines.com

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

Blueprint Medicines Corporation Fundamentals Summary

How do Blueprint Medicines's earnings and revenue compare to its market cap?
BPMC fundamental statistics
Market CapUS$2.86b
Earnings (TTM)-US$717.56m
Revenue (TTM)US$272.28m

10.5x

P/S Ratio

-4.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BPMC income statement (TTM)
RevenueUS$272.28m
Cost of RevenueUS$748.58m
Gross Profit-US$476.30m
Other ExpensesUS$241.26m
Earnings-US$717.56m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-11.99
Gross Margin-174.93%
Net Profit Margin-263.54%
Debt/Equity Ratio21.6%

How did BPMC perform over the long term?

See historical performance and comparison